Genetic Causes of Severe Childhood Brain Disorders Found Using New Computational Methods that Process Clinical Features at Scale

Philadelphia, August 26, 2020 – A team of researchers at Children’s Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) have combined clinical information with large-scale genomic data to successfully link characteristic presentations of childhood epilepsies with specific genetic variants. The findings were published today in the American Journal of Human Genetics.

Developmental and Epileptic Encephalopathies (DEE), a group of severe brain disorders that can cause difficult-to-treat seizures, cognitive and neurological impairment, and, in some cases, early death, are known to have more than 100 underlying genetic causes. However, matching characteristic clinical features and outcomes with specific genetic mutations can be especially daunting given the large number of genetic causes, each of which is very rare.

When genetic information is collected, a person’s phenotype – or clinical features – are typically also documented. However, while genetic information is collected in a standardized manner, the same is not true when describing clinical symptoms, which makes it difficult when trying to pinpoint whether certain genetic mutations are responsible for specific clinical features.

Building upon their previous work, researchers from CHOP utilized the Human Phenotype Ontology (HPO), which provides a standardized format to characterize a patient’s phenotypic features and allows clinical data to be used at a similar level as genetic data.

“For this study, we used phenotypic and genetic information that had been collected in several important cohorts for more than a decade,” said Ingo Helbig, MD, attending physician at ENGIN, director of the genomic and data science core of ENGIN and lead investigator of the study. “In this study alone, we found associations of 11 genetic causes with specific phenotypes. Without methods to systematically analyze clinical data, we could not have possibly done this previously, even with this robust cohort of patients.”

In total, the study team analyzed 31,742 HPO terms in 846 patients with existing whole exome sequencing data. Some examples of causative genes in DEE identified in this study were SCN1A, which was associated with complex febrile seizures and focal clonic seizures; STXBP1, which was associated with absent speech; and SLC6A1, which was associated with EEG with generalized slow activity. In total, 41 genes with variants presented in at least two individuals, and 11 of those genes showed significant similarity between phenotypes of the patients with changes in these genes. Using a statistical analysis, the researchers showed that this was more than would be possible via chance.

“Traditionally, many of the genetic epilepsies that we now develop treatments for were described because of a specific set of clinical features that stood out. However, this type of traditional description of new diseases requires patients to be seen by the same provider or within the same center. What we have done with this study is re-engineered the cognitive process that goes on when clinicians discover a new syndrome,” Helbig said. “We have developed a computational mechanism to replicate this type of discovery from large, de-identified clinical data. As the amount of deep phenotypic data available to us increases, we now have the ability to identify novel genetic causes of particularly severe forms of epilepsy that are targets for new treatments.”

This study was supported by The Hartwell Foundation through an Individual Biomedical Research Award, the National Institute for Neurologic Disorders and Stroke grants K02 NS112600 and U54 NS108874, the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Intellectual and Developmental Disabilities Research Center at CHOP and the University of Pennsylvania through grant U54 HD086984, and intramural funds of CHOP through ENGIN.

Research was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award UL1TR001878 and the Institute for Translational Medicine and Therapeutics’ Transdisciplinary Program in Translational Medicine and Therapeutics at the Perelman School of Medicine of the University of Pennsylvania. The study also received support through the EuroEPINOMICS-Rare Epilepsy Syndrome Consortium, the German Research Foundation through award HE5415/3-1, the German Research Foundation through awards HE5415/5-1, HE5415/6-1 and WE4896/3-1, the DFG Research Unit FOR2715 through awards We4896/4-1 and He5415/7-1, and the Genomics Research and Innovation Network.

Additional support was provided by the International League Against Epilepsy, an NIH Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant T32 NS091008, and the Wellcome Trust 4ward North Clinical PhD Academy.

Galer et al, “Semantic similarity analysis reveals robust gene-disease relationships in developmental and epileptic encephalopathies.” Am J Hum Gen, online August 26, 2020. DOI: 10.1016/j.ajhg.2020.08.003.

About Children’s Hospital of Philadelphia: Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide.  Its pediatric research program is among the largest in the country.  In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu